#151022

Anti-IL12 [1-1A4]

Cat. #151022

Anti-IL12 [1-1A4]

Cat. #: 151022

Sub-type: Primary antibody

Unit size: 100 ug

Availability: 1-2 weeks

Target: Interleukin-12 (IL12) p40 subunit

Class: Monoclonal

Application: IHC ; ELISA ; IHC ; RIA ; WB

Reactivity: Human

Host: Mouse

£300.00

This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.

Contributor

Inventor: Rosemonde Banks

Institute: University of Leeds

Tool Details
Target Details
Applications
Handling
References

Tool Details

*FOR RESEARCH USE ONLY (for other uses, please contact the licensing team)

  • Name: Anti-IL12 [1-1A4]
  • Alternate name: Interleukin 12; Cytotoxic Lymphocyte Maturation Factor 4 KDa Subunit; NK Cell Stimulatory Factor Chain; Interleukin-12 Beta Chain; IL-12 Subunit P4; CLMF P4; NKSF2; Natural Killer Cell Stimulatory Factor; IL12; Subunit P4; Interleukin 12; CLMF2; IMD29; NKSF; P4
  • Research fields: Immunology
  • Clone: 1-1A4
  • Tool sub type: Primary antibody
  • Class: Monoclonal
  • Conjugation: Unconjugated
  • Reactivity: Human
  • Host: Mouse
  • Application: IHC ; ELISA ; IHC ; RIA ; WB
  • Description: Monoclonal antibody which binds p40 subunit of interleukin-12.
  • Immunogen: Recombinant human IL-12 produced in Baculovirus.
  • Immunogen uniprot id: P29459
  • Isotype: IgG1
  • Myeloma used: Sp2/0-Ag14

Target Details

  • Target: Interleukin-12 (IL12) p40 subunit
  • Target background: IL-12 is a heterodimeric cytokine comprised of p35 and p40 subunits. IL-12 plays a central role in cell-mediated immunity, promoting the differentiation of CD4+ T cells to the Th1 subset and of CD8+ T cells into mature cytotoxic T lymphocytes (CTLs). Interleukin 12 (IL-12) is produced by dendritic cells, macrophages, neutrophils, and human B-lymphoblastoid cells in response to antigenic stimulation. IL-12 is a potent stimulator of Natural Killer cells. IL-12 therapy has been suggested as a method of enhancing cytocidal anti-tumour immune responses. This antibody recognises the p40 subunit of human IL-12 and binds to both the free subunit and the p35/p40 heterodimer. It reacts with both stimulated and unstimulated monocytes in immunohistology.

Applications

  • Application: IHC ; ELISA ; IHC ; RIA ; WB

Handling

  • Format: Liquid
  • Concentration: 1 mg/ml
  • Unit size: 100 ug
  • Storage buffer: PBS with 0.02% azide
  • Storage conditions: Store at -20° C frozen. Avoid repeated freeze / thaw cycles
  • Shipping conditions: Shipping at 4° C

References

  • Nagashima et al. 2008. Anticancer Res. 28(2B):1277-83. PMID: 18505066.
  • Prognostic significance of the local expression of interleukin-12 in patients with advanced gastric cancer.
  • Nakayama et al. 2004. Anticancer Res. 24(5C):3289-94. PMID: 15515423.
  • Relationships between local and systemic expression of interleukin-12 and plasma levels of vascular endothelial growth factor in patients with gastric cancer.
  • Carter et al. 1997. Hybridoma. 16(4):363-9. PMID: 9309427.
  • Production and characterization of monoclonal antibodies to human interleukin-12.